Wall Street brokerages predict that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will report earnings of ($0.26) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.37). Dicerna Pharmaceuticals reported earnings of ($0.90) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 71.1%. The business is scheduled to report its next quarterly earnings report on Thursday, March 14th.

Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.11). The company had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.67 million. Dicerna Pharmaceuticals had a negative net margin of 1,418.01% and a negative return on equity of 63.24%.

A number of brokerages have recently issued reports on DRNA. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, November 6th. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 23rd. Stifel Nicolaus upped their target price on shares of Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, B. Riley upgraded shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $13.50 to $21.00 in a research note on Tuesday, November 6th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $20.44.

In related news, Director Brian K. Halak sold 245,096 shares of the stock in a transaction dated Tuesday, October 30th. The shares were sold at an average price of $13.92, for a total transaction of $3,411,736.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Brian K. Halak sold 564,300 shares of the stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $13.66, for a total transaction of $7,708,338.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,146,697 shares of company stock worth $15,625,892. 19.85% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp increased its stake in shares of Dicerna Pharmaceuticals by 63.7% in the first quarter. Northern Trust Corp now owns 59,384 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 23,102 shares during the period. BlackRock Inc. increased its stake in shares of Dicerna Pharmaceuticals by 136.5% in the first quarter. BlackRock Inc. now owns 277,493 shares of the biopharmaceutical company’s stock valued at $2,652,000 after purchasing an additional 160,172 shares during the period. Millennium Management LLC increased its stake in shares of Dicerna Pharmaceuticals by 509.1% in the first quarter. Millennium Management LLC now owns 407,530 shares of the biopharmaceutical company’s stock valued at $3,896,000 after purchasing an additional 340,623 shares during the period. Bank of Montreal Can acquired a new stake in shares of Dicerna Pharmaceuticals in the second quarter valued at approximately $898,000. Finally, Emerald Advisers Inc. PA increased its stake in shares of Dicerna Pharmaceuticals by 2,002.5% in the second quarter. Emerald Advisers Inc. PA now owns 603,508 shares of the biopharmaceutical company’s stock valued at $7,393,000 after purchasing an additional 574,804 shares during the period. Hedge funds and other institutional investors own 76.16% of the company’s stock.

Shares of Dicerna Pharmaceuticals stock opened at $13.50 on Friday. Dicerna Pharmaceuticals has a 1 year low of $6.80 and a 1 year high of $17.98.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Featured Article: Why do companies issue stock splits?

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.